苏拉明直接准PI3K,通过恢复肠道屏障和激活自细胞来缓解实验性结肠炎
Bing Yan1, Xinjie Mao2, Shimin Wang3
1Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Chongqing Municipal Health Commission Key Laboratory of Precision Diagnosis and Treatment of Liver Cirrhosis and Complications, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China; Department of Endoscopy and Digestive System, Guizhou Provincial People's Hospital, Guiyang, China.
抗寄生虫药物苏拉明在性结肠炎 (UC) 治疗方面表现有前途. 它修复了肠道屏障,并通过抑制PI3K/AKT/mTOR通路来增强自,为UC提供了潜在的新疗法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 性结肠炎 (UC) 涉及肠道屏障受损和自减少.
- 抗寄生素Suramin具有抗炎作用,但其UC机制尚不清楚.
研究的目的:
- 为了评估suramin在实验性结肠炎中的保护作用.
- 为了确定参与苏拉明作用的分子点和途径.
主要方法:
- 使用了一种硫酸德克斯 (DSS) 诱导的小鼠结肠炎模型.
- 评估了Suramin对临床症状,屏障完整性 (紧密结合蛋白) 和自的影响.
- 通过网络分析,分子对接和拉下测试,PI3K被确定为目标.
主要成果:
- 苏拉明剂量依赖性降低了结肠炎的严重程度,改善了屏障功能和增强了自.
- 苏拉明直接与PI3K p85α结合,从而抑制PI3K/AKT/mTOR通路.
- 重新激活PI3K消除了苏拉明的保护作用.
结论:
- 苏拉明通过抑制PI3K/AKT/mTOR信号传递来防止实验性结肠炎.
- 这种抑制刺激了自并加强了肠道上皮屏障.
- 苏拉明是性结肠炎的潜在药物重用候选者.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
相关概念视频
Drugs that Destabilize Microtubules
PI3K/mTOR/AKT Signaling Pathway
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
